HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
about
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usageImmunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS.beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaquesA human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesLimited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimenComparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculationEvidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesImmunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strainLive, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesQualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.HIV/AIDS vaccines: a need for new concepts?Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS.A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques.Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection.Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus.
P2860
Q24531468-D4CDAC70-052C-456E-8177-3E8F3B5635F9Q24531479-85965EAA-6D66-4BBF-AE52-6ADA77208E42Q30234577-96C6B179-FD87-4DCC-A3D3-EA6478C3C2F4Q32157115-C62C6836-1550-463D-AAF6-9DD32C091EE3Q33500138-DBABFF77-F70F-4D5E-AF0B-025912B687E4Q33555112-4C314810-31C3-4D1F-BBC7-872F55EFB1A6Q33603494-D13437A6-75CA-4116-BBD4-10BA86BCC722Q33639684-DD0D5959-7660-49C7-B8CF-4C06CA1B57DBQ33645053-D2E8F948-848D-49E1-8B45-55F45AA7C69BQ33715758-0A827011-DF4E-4E6A-8AEF-E9A817C985C8Q33786386-41695A20-3129-47F0-8E5B-9B088741882DQ33788701-5851A906-54DF-4488-ADE7-40EF8822883DQ33803217-C17E0BC0-C23B-40F6-B652-CA08529961E3Q33810203-A83F2D2A-141D-4FE9-B780-B31F1B227327Q33819493-A6082E87-2EB8-4053-BFFA-F9A87E1D40CDQ33843554-7B0C9866-097C-4568-A365-7890C17FB32CQ34069214-616A09D0-BEC1-40B6-B1C9-5AE3C4465AD4Q34334135-8B97DCAF-F4C0-4C50-874F-8F0322C11556Q35049812-2DECFE33-ACA4-48A2-9425-40A8692D885FQ35848078-98E4EFF6-EAC6-4AFB-AF1E-30EF93AACBACQ35863652-C6A6C3D4-C40C-43E3-9498-4EEC33980B73Q35872988-A0349FD9-64B6-4DE6-8BEE-D64722DF9C3AQ35897786-C42E1E93-03F9-4E9D-9B37-7ADDCB381E61Q36424574-0C92FB4E-D201-4142-AC4C-E386D42AEDC2Q37009569-61BD3EA2-6955-4AD7-AE1A-8FB439294482Q37010374-BF58733B-82A4-435A-8901-9C047A0C8BA5Q37344236-A5ED3A1F-CE8C-4868-A921-BC21459B674EQ39457063-5F688843-B1CB-48A0-B025-D956B61D9A0AQ39579134-F48C88D7-55AB-4011-BDE5-D3627AFD5490Q39583691-2D8CC866-78DC-4C76-8D15-7BB1480771D9Q39597776-2D7077B4-33AE-4068-B46D-7F71ABE483B1Q39699309-8DA4D285-C6C1-4C6E-8750-A463B5D38B7EQ43690745-534DB720-790A-4C46-89A9-3B1BF538CDCFQ44592013-62FF9318-4612-4D4B-8EC4-8608F355D7CAQ45745783-D0B9C5D4-BF4A-4A67-9E84-F15B139C3A41
P2860
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@en
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@nl
type
label
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@en
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@nl
prefLabel
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@en
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@nl
P2093
P1433
P1476
HIV-1 envelope-elicited neutra ...... and virus load in chimpanzees.
@en
P2093
De Wilde M
Francotte M
Rosenberg M
Thiriart C
P304
P356
10.1016/0264-410X(94)90185-6
P407
P577
1994-09-01T00:00:00Z